CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study of Ultra-Rapid-Acting Insulin Analog Candidates

CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study of
Ultra-Rapid-Acting Insulin Analog Candidates

DANBURY, Conn., Jan. 24, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier
today by Biodel Inc. (Nasdaq:BIOD), one reference to BIOD-238 should have been
BIOD-250 in the fourth paragraph. The corrected paragraph follows:

Local injection site discomfort was measured with a 100 mm visual analog scale
(VAS) and patient questionnaires. 100 mm is defined as the worst possible
discomfort and 0 mm is defined a having no discomfort. In the trial, the VAS
score was numerically lower, but not significantly different for BIOD-250
compared to Humalog^® (mean VAS scores of 2.7 mm and 8.2 mm for BIOD-250 and
Humalog^®, respectively; p=NS). The VAS score for BIOD-238 was significantly
higher than that associated with Humalog^® (mean VAS score of 24.2 mm, p=0.029
vs. Humalog^®).

BIOD-G

CONTACT: Seth D. Lewis, +1-646-378-2952
 
Press spacebar to pause and continue. Press esc to stop.